Press Releases

2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

2013
Dec 2013 | Download as pdf

Soluble Therapeutics Inc. has a second cash infusion that will help the company continue its work in protein-based pharmaceuticals as well as more

Dec 2013 | Download as pdf

StemBioSys, a San Antonio-based bioscience startup, is looking to raise $8 million in new Series A investor funding. The company has already secured more

29 Nov 2013 | Download as pdf

Medical-device firm Xenex attracts big Investment. When Rackspace Hosting co-founder Morris Miller more

25 Nov 2013 | Download as pdf

Xenex CEO expects 2013 revenues to be north of $20 Million.

Xenex Disinfection Services’ Morris Miller expects more significant growth for the medical-device company.

Xenex Disinfection System’s decision to relocate from Austin to San Antonio last year has paid off in a big way.

The medical-device company has found solid financial footing since establishing roots in a city which has made it a priority to become a bigger player in the bioscience arena.

Xenex CEO Morris Miller tells me that the company is on pace to generate in excess of $20 million in revenues in 2013. The company generated about $5.8 million in 2012.

Earlier this week, I reported that Xenex recently secured more than $11 million in new investor funding. Miller says a portion of those funds will be used to grow the company’s workforce.

Miller says Xenex currently employs about 75 people. That number could double over the next two years, with most of that workforce based in San Antonio.

Xenex officials are optimistic that access to venture capital in San Antonio will continue to increase. Additional investor support could position the company for still more growth.

“We can do this here,” says Miller about the prospect for using the assets and support available in San Antonio to continue to expand Xenex’s presence in the medical device space. back

21 Nov 2013 | Download as pdf

Xenex Secures $11.3 Million in Funding; Superbug Zapping Robot Enhances Patient Safety by Eliminating Pathogens that Cause Hospital Infections more

14 Nov 2013 | Download as pdf

DNAtrix Announces Treatment of First Patient in Study with Recurrent Glioblastoma Using DNX-2401 and Temozolomide more

Sept 2013 | Download as pdf

Medical Innovation iTClamp Hemorrhage Control System Used for First Time in United States more

Aug 2013 | Download as pdf

BiO2 Medical Executes Full Commercialization in the United Kingdom Partnering with United Drug Medical (UDM) as an Exclusive Distributor for the Angel® Catheter more

July 2013 | Download as pdf

DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus more

July 2013 | Download as pdf

ArthroCare Announces Acquisition of ENTrigue Surgical, Inc more

May 2013 | Download as pdf

Vidacare projects big revenue spike for 2013 more

May 2013 | Download as pdf

BiO2 Medical's IDE Application for the Angel(TM) Catheter Receives FDA Approval more

May 2013 | Download as pdf

Medical Device Firm iTraumaCareTM Receives FDA 510(k) Clearance for iTClampTM Hemorrhage Control System more

May 2013 | Download as pdf

BiO2 Medical's IDE Application for the Angel(TM) Catheter Receives FDA Approval more

March 2013 | Download as pdf

Woman, 80, gets new blood clot prevention device more

Feb 2013 | Download as pdf

BioDtech, Inc. Issued New United States Patent more

Jan 2013 | Download as pdf

Successful Completion of Santalis Pharmaceuticals Initial Clinical Trials more